Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.53 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.53 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.53 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.53 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.44 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL547062 | 0.95 | SLC29A1 (0.57) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| Phosphoric Acid SCHEMBL4575970 | 0.91 | SLC28A1 (0.53) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| Phosphoric Acid SCHEMBL20769288 | 0.91 | SLC28A1 (0.53) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL4419700 | 0.87 | P2RY2 (0.57) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL7027805 | 0.86 | P2RY2 (0.49) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL446253 | 0.84 | SLC29A1 (0.49) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL6271158 | 0.84 | SLC29A1 (0.59) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL3969711 | 0.83 | SLC29A1 (0.60) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL13467881 | 0.82 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL14989543 | 0.82 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030170644-A1 | Method for screening nucleic acid catalysts | RIBOZYME PHARMACEUTICALS, INC. | 2003-09-11 | — | — | US | disclosed |
| US-20030144489-A1 | Method for screening nucleic acid catalysts | RIBOZYME PHARMACEUTICALS, INC. | 2003-07-31 | — | — | US | disclosed |
| EP-1321521-A1 | Ribozymes directed against flt-1 | RIBOZYME PHARMACEUTICALS, INC. (US) | 2003-06-25 | — | — | EP | disclosed |
| US-6548657-B1 | Synthesis of ribozyme libraries and gene sequences | RIBOZYME PHARMACEUTICALS, INC. | 2003-04-15 | — | — | US | disclosed |
| US-6280936-B1 | USEFUL FOR CLEAVAGE OF RIBONUCLEIC ACID (RNA) AND DEOXYRIBONUCLEIC ACID | RIBOZYME PHARMACEUTICALS, INC. | 2001-08-28 | — | — | US | disclosed |
| EP-0980424-A2 | ENZYMATIC NUCLEIC ACIDS: SYNTHESIS, SELECTION AND USE | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-02-23 | — | — | EP | disclosed |
| WO-1998050530-A9 | ENZYMATIC NUCLEIC ACIDS: SYNTHESIS, SELECTION AND USE | RIBOZYME PHARM INC (US) | 1999-03-25 | — | — | WO | disclosed |
| WO-1998050530-A2 | ENZYMATIC NUCLEIC ACIDS: SYNTHESIS, SELECTION AND USE | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030170644-A1 | Method for screening nucleic acid catalysts | RNGTT, POLRMT, RNASE1 | SLC29A1 564/4885SLC28A1 868/4885SLC28A2 815/4885 |
| US-20030144489-A1 | Method for screening nucleic acid catalysts | POLM, POLRMT, RNGTT | SLC29A1 677/4885SLC28A1 1028/4885SLC28A2 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.